-
1 Comment
Changzhou Qianhong Biopharma CO.,LTD is currently in a long term downtrend where the price is trading 2.0% below its 200 day moving average.
From a valuation standpoint, the stock is 70.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.
Changzhou Qianhong Biopharma CO.,LTD's total revenue rose by 68.7% to $508M since the same quarter in the previous year.
Its net income has increased by 78.4% to $83M since the same quarter in the previous year.
Finally, its free cash flow grew by 147.8% to $162M since the same quarter in the previous year.
Based on the above factors, Changzhou Qianhong Biopharma CO.,LTD gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CNE100001070 |
| Market Cap | 12B |
|---|---|
| PE Ratio | 27.12 |
| Target Price | 7 |
| Dividend Yield | 1.3% |
| Beta | 0.15 |
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its products. The company was founded in 1971 and is headquartered in Changzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002550.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
